SCHEMBL6325997

SCHEMBL6325997

CC(=O)N1C(=O)C(=C(O)c2ccccc2)c2ccccc21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 4/20 0.63
ALDH1A1 P00352 5/20 0.49
MAPT P10636 4/20 0.49
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
USP2 O75604 1/20 0.49
CASP1 P29466 1/20 0.49
BRCA1 P38398 1/20 0.49
LMNA P02545 3/20 0.49
HTT P42858 2/20 0.49
ALOX15 P16050 1/20 0.49
HSD17B10 Q99714 1/20 0.49
NOTUM Q6P988 2/20 0.42
TRPA1 O75762 1/20 0.42
NPC1 O15118 1/20 0.42
MTOR P42345 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 1/20 0.41
NOX1 Q9Y5S8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6325992 1.00 CES1 (0.63) CES1ALDH1A1MAPTKMT2AMEN1
SCHEMBL25681839 1.00 CES1 (0.63) CES1ALDH1A1MAPTKMT2AMEN1
SCHEMBL8012190 0.90 CES1 (0.55) CES1ALDH1A1MAPTKMT2AMEN1
SCHEMBL8012191 0.90 CES1 (0.55) CES1ALDH1A1MAPTKMT2AMEN1
SCHEMBL6328153 0.86 CES1 (0.58) CES1ALDH1A1MAPTKMT2AMEN1
SCHEMBL6328148 0.86 CES1 (0.58) CES1ALDH1A1MAPTKMT2AMEN1
SCHEMBL6325176 0.85 ALDH1A1 (0.50) CES1ALDH1A1MAPTKMT2AUSP2
SCHEMBL6325179 0.85 ALDH1A1 (0.50) CES1ALDH1A1MAPTKMT2AUSP2
SCHEMBL3935792 0.84 CES1 (0.56) CES1ALDH1A1MAPTKMT2AMEN1
SCHEMBL3936277 0.84 CES1 (0.52) CES1ALDH1A1MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6855710-B2 Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-02-15 US disclosed
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-03-25 US disclosed
EP-1115704-B1 NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES BOEHRINGER INGELHEIM PHARMA (DE) 2003-06-18 EP disclosed
EP-1115704-A1 NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES Boehringer Ingelheim Pharma KG (DE) 2001-07-18 EP disclosed
WO-2000018734-A1 NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES BOEHRINGER INGELHEIM PHARMA KG (DE) 2000-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs CDK1, CDK2, CDK3 CES1 2292/4885ALDH1A1 1810/4885MAPT 3817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.